KEGG   DISEASE: Secondary hyperparathyroidismHelp
Entry
H01669                      Disease                                

Name
Secondary hyperparathyroidism
Description
Secondary hyperparathyroidism (SHPT) is a chronic and progressive disorder characterized by elevated serum parathyroid hormone (PTH), parathyroid gland hyperplasia, and disturbances in mineral metabolism, mainly calcium and phosphorus. SHPT is generally caused by diffuse parathyroid hyperplasia in response to prolonged reduced levels of extracellular calcium from various secondary aetiologies. Although it is initially and adaptive response to a variety of stimuli resulting mainly in extracellular hypocalcaemia (vitamin D deficiency, chronic kidney disease, idiopathic hypercalciuria, calcium malabsorption), long-standing SHPT may eventually develop into autonomous HPT (ie, tertiary HPT). Because SHPT is a compensatory mechanism of the parathyroid glands, it commonly resolves with normalization of calcium and phosphorus homeostasis. After excluding reversible secondary aetiologies, first-line treatment of irreversible SHPT (often related to chronic kidney disease) mainly involves medical therapies.
Category
Endocrine disease
Brite
Human diseases [BR:br08402]
 Endocrine and metabolic diseases
  Parathyroid diseases
   H01669  Secondary hyperparathyroidism
Human diseases in ICD-11 classification [BR:br08403]
 05 Endocrine, nutritional or metabolic diseases
  Endocrine diseases
   Disorders of the parathyroids or parathyroid hormone system
    5A51  Hyperparathyroidism
     H01669  Secondary hyperparathyroidism
BRITE hierarchy
Drug
Calcifediol [DR:D00122]
Cinacalcet hydrochloride [DR:D03505]
Doxercalciferol [DR:D01009]
Etelcalcetide hydrochloride [DR:D10677]
Other DBs
ICD-11: 5A51.1
ICD-10: E21.1
MeSH: D006962
Reference
  Authors
Cozzolino M, Tomlinson J, Walsh L, Bellasi A
  Title
Emerging drugs for secondary hyperparathyroidism.
  Journal
Expert Opin Emerg Drugs 20:197-208 (2015)
DOI:10.1517/14728214.2015.1018177
Reference
  Authors
Duan K, Gomez Hernandez K, Mete O
  Title
Clinicopathological correlates of hyperparathyroidism.
  Journal
J Clin Pathol 68:771-87 (2015)
DOI:10.1136/jclinpath-2015-203186
Reference
PMID:27479950 (description, drug)
  Authors
Yuen NK, Ananthakrishnan S, Campbell MJ
  Title
Hyperparathyroidism of Renal Disease.
  Journal
Perm J 20:78-83 (2016)
DOI:10.7812/TPP/15-127
Reference
PMID:28277829 (drug)
  Authors
Hamano N, Komaba H, Fukagawa M
  Title
Etelcalcetide for the treatment of secondary hyperparathyroidism.
  Journal
Expert Opin Pharmacother 18:529-534 (2017)
DOI:10.1080/14656566.2017.1303482
Reference
PMID:9708607 (drug)
  Authors
Akiba T, Marumo F, Owada A, Kurihara S, Inoue A, Chida Y, Ando R, Shinoda T, Ishida Y, Ohashi Y
  Title
Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
  Journal
Am J Kidney Dis 32:238-46 (1998)
DOI:10.1053/ajkd.1998.v32.pm9708607

» Japanese version

DBGET integrated database retrieval system